Mobile-health Network Solutions Class A Ordinary Shares
Mobile-health Network Solutions, an investment holding company, provides telehealth solutions primarily in Singapore. The company operates in two segments: Telemedicine and Other Services and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The company also provides a suite of medical-related and other services, including teleconsultations and health check-up services, vaccinations, skin and aesthetics services, and other services. In addition, it offers healthcare and wellness products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical services. The company was founded in 2009 and is headquartered in Singapore.
Open MNDR dashboard ↗Sana Biotechnology, Inc. Common Stock
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Open SANA dashboard ↗